Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
|Articles|November 2, 2013
- Pharmaceutical Technology-11-02-2013
- Volume 37
- Issue 11
Pharmaceutical Technology, November 2013 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2013 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 13 years ago
Report from Brazil November 2013almost 13 years ago
Applying Catalysis to Optimize API Synthesisalmost 13 years ago
Predicting Long-Term Storage Stability of Therapeutic Proteinsalmost 13 years ago
Control of Elemental Impuritiesalmost 13 years ago
Automation System Improves Operational Insightalmost 13 years ago
Disposable Applications in Demand by Biopharmaalmost 13 years ago
Solvent-Free Coating of Traditional and User-Friendly Dosage Formsalmost 13 years ago
Congress Revises Rules for Drug Compounding and Supply-Chain Securityalmost 13 years ago
Can Pharma Defy Gravity at the Patent Cliff?almost 13 years ago
Defining and Presenting Overkill Cycle ValidationAdvertisement
Related to this article
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
The new initiative aims to apply traceable AI and science to expand care worldwide by translating discovery into tools that accelerate drug development.
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5